| manufacturer_name | ndc_number | drug_product_description | date_introduced_to_market | wac_at_introduction | marketing_pricing_plan_description | marketing_pricing_plan_non_public_indicator | estimated_number_of_patients | breakthrough_therapy_indicator | priority_review_indicator | acquisition_date | acquisition_price | acquisition_price_non_public_indicator | acquisition_price_comment | general_comments | supporting_documents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi USA LLC | 65219019030 | VORICONAZOLE (voriconazole) 200mg Each | 2021-02-02 | 60.0000 | None | 1 | 2000 | None | None | None | None | None | None | None | None |
| Fresenius Kabi USA LLC | 63323087550 | FOSCARNET 6000 mg per 250 mL | 2021-02-11 | 472.7700 | None | 1 | 1000 | None | None | None | None | None | None | FOSCARNET is not an acquired product. | None |
| Fresenius Kabi USA LLC | 65219020005 | TEMSIROLIMUS (temsirolimus) 25mg/ml | 2021-05-03 | 1180.0000 | None | 1 | 2186 | None | None | None | None | None | None | None | None |